Blog

My doctor prescribed a drug off-label: will insurance pay for it?

What off-label means, how plans and Part D judge it, what the prescriber sends, the appeal route and cash alternatives, with a sample request outline.

Maybe. Off-label prescribing is legal, common and often good medicine, but a health plan is not required to pay for a use that the FDA has not approved, and many plans start from "not covered" and then look for evidence. Whether yours pays depends on the plan's written policy, the strength of the published evidence for your use, what your prescriber documents and, in Medicare drug plans, a specific rule about which uses can be covered at all.

The playbook below follows the order in which things happen: understand what the label means, learn the plan's rule, have the prescriber build the request, know the appeal route, and line up cash and assistance options in parallel. It is not medical advice. Whether the drug is right for you is a question for your prescriber.

Step 1: Understand what "off-label" means and why it is common

When the FDA approves a drug, it approves it for particular uses: certain conditions, ages, doses and routes, described in the drug's labeling. A drug is prescribed off-label when it is used for a condition, an age group, a dose or a form of administration that is not in that labeling. The FDA regulates what the maker may advertise, not what a licensed prescriber may prescribe.

Off-label use is common for understandable reasons. Research can run ahead of the label. A drug approved for one condition may help a related one. Children are often given drugs that were tested only in adults, because pediatric trials are costly. Cancer treatment regularly combines drugs in ways the labels do not list. Rare conditions may have no approved drug at all. Many experienced clinicians prescribe off-label routinely, and professional guidelines often recommend such uses.

The practical meaning for insurance: the plan's first look at the request will not match a labeled indication, and the question becomes whether the evidence is strong enough to treat it as medically necessary.

Step 2: Find out how your plan evaluates off-label use

The rules come from three places, and they differ by plan type.

Commercial plans (employer and marketplace). The plan's written medical or pharmacy policy decides. Many plans cover an off-label use if it meets criteria such as:

  • The drug is FDA-approved for something.
  • The use is supported by published evidence of effectiveness, often in peer-reviewed literature or in recognized drug reference books called compendia.
  • It is medically necessary for the patient (see medical necessity), meaning other treatments were tried, are inappropriate or are not available.
  • It is not considered experimental or investigational.

Other plans say off-label uses are not covered unless approved in advance, and others simply deny and leave the prescriber to appeal. Look in the plan's drug list for the drug's restrictions and in the plan's clinical policies for a statement on off-label use. If you cannot find it, ask the plan for the policy in writing.

State laws. Some states have laws about off-label coverage, such as requiring coverage of cancer drugs that are used off-label when the use is supported by recognized references. The details differ by state and generally apply to insured plans, not to employer plans that fund their own benefits, which follow federal rules instead. Your state insurance department can tell you whether such a law applies. The guide what to do when your plan will not cover a drug you need covers the other routes.

Medicare Part D. Part D has a narrower rule. A Part D plan may cover a drug only for a medically accepted indication, which means a use that is either FDA-approved or supported by citations in specific drug compendia named in the law (the American Hospital Formulary Service Drug Information, and the DRUGDEX information system). If your use is off-label and not supported by one of those references, a Part D plan cannot cover it, whatever the prescriber's judgment, and an appeal will not change that. If the use is supported, the plan can cover it, usually after prior authorization. The guide Medicare Part D explained: drug plans, formularies and costs covers the structure of Part D. Medicare Part B, which covers drugs given in a doctor's office, applies its own rules for off-label use, often including cancer drugs.

Medicaid. State Medicaid programs follow federal rules about covered outpatient drugs and add their own prior authorization criteria. The state Medicaid agency or the Medicaid plan can say how it treats an off-label request.

Step 3: Ask the prescriber what the evidence is

Before the request goes in, have a short conversation with the prescriber. It is a normal question, not a challenge. Useful things to ask:

  1. Why this drug for me, and what is the evidence for this use? Is it in a clinical guideline?
  2. What have I already tried, and what happened?
  3. Is the plan likely to want a prior trial of another drug first?
  4. Which published studies or references would you cite?
  5. What if the plan says no? Do you have a second option?

The answers go straight into the request, and they help you judge how much to expect.

Step 4: What the prescriber submits

The request is usually a prior authorization or a formulary exception, filed by the prescriber's office through the plan's form or portal. The guide how prior authorization works and what to do when it is denied describes the process. For an off-label use, the packet should show the plan why the evidence supports your use. It should include:

  • The diagnosis and the date, with supporting tests or records.
  • A statement that the use is off-label and why the prescriber chose it for you.
  • The treatment history: drugs tried, doses, dates, outcomes, reasons for stopping.
  • Citations: published studies, guideline statements from professional societies, and any compendia entries supporting the use.
  • The goals of treatment and how response will be measured.
  • A statement of why alternatives that are approved for the condition are not suitable, if that applies.

A sample outline for the request letter

The prescriber writes the letter. You can use this outline to ask for the right things. The details in brackets are placeholders.

  1. Header. Patient name, date of birth, plan ID, the drug and dose requested, the diagnosis and its code, and the date.
  2. Request. "I am requesting coverage of [drug] for [condition]. This is an off-label use supported by the evidence below."
  3. Clinical summary. Two or three sentences on the diagnosis, severity and course.
  4. Prior treatment. A list of each drug tried, the dose, the dates and the result.
  5. Rationale. Why this drug, and why now. "Approved alternatives were tried and [failed or caused X], or are contraindicated because [reason]."
  6. Evidence. The citations: studies with their authors and journals, guideline statements, compendia listings.
  7. Plan for monitoring. How you will measure whether it works and when you will reassess.
  8. Urgency, if it applies. "Delay could seriously jeopardize the patient's health. I request expedited review."
  9. Contact. Direct phone number for a peer-to-peer discussion.

Ask for a copy of the final letter and the attachments. The claim denial appeal letter builder helps you assemble the same elements if an appeal is needed.

Step 5: If the plan denies

The denial notice states the reason, the criteria and the deadline to appeal. Off-label denials usually say one of the following, and each points to a fix.

Reason stated What usually helps
Not an FDA-approved use Add compendia citations, published trials and guideline statements
Experimental or investigational Show the volume and quality of evidence; ask for external review, which commonly covers this kind of denial
Step therapy not completed Document why approved alternatives were tried or are unsuitable; ask for a step therapy exception
Missing information Resubmit with the missing records
Not medically necessary Strengthen the clinical letter and add objective findings

The appeal has three stages in most plans. First, an internal appeal to the plan, which for most plans you have at least 180 days to file. Second, a peer-to-peer call between the prescriber and a plan reviewer, which the prescriber can ask for at the start of the appeal or before; peer-to-peer review mistakes that cost patients the approval describes the common missteps. Third, an independent external review, where a reviewer outside the plan decides. For insured plans, the external review process is generally open for medical necessity denials and for denials the plan labels experimental or investigational, so an off-label denial often qualifies. The notice states the deadline. The guide how to appeal a denied health insurance claim, step by step covers each step.

In Medicare Part D, the sequence is different: a coverage determination, then a redetermination by the plan, then review by an independent entity and further levels. The deadlines are short, and the plan's notice and the Part D coverage determination and exception: the step order that works post describe them. Remember that for Part D the question is whether the use is a medically accepted indication, so strong evidence supporting a use outside the named compendia cannot be used to override that rule.

Step 6: Line up alternatives while you wait

Do these in parallel, not after a denial.

  • Ask what the cash price is. Many off-label drugs are older, low-cost generics. A discount card or the pharmacy's cash price may be less than a plan copay, and for a low-cost drug, the whole request may not be worth the delay. The trade-off is that cash purchases may not count toward your deductible. The post when paying cash for a generic beats using my insurance explains it.
  • Ask about a different approved drug. If an FDA-approved drug exists for your condition and the plan covers it, ask the prescriber whether it is an acceptable alternative, or what the reasons are against it. Those reasons belong in the request.
  • Ask about manufacturer assistance. Many patient assistance and copay programs are limited to FDA-approved uses, so off-label use may not qualify, but check the specific program's rules with the prescriber's office.
  • Ask about charitable foundations and clinic programs. Some help with cost sharing for particular conditions. The prescriber's office or a hospital social worker may know them.
  • Ask about clinical trials. If your use is still being studied, a trial may provide the drug, and a research study may be an option.
  • Ask about samples. Prescribers sometimes can give a short supply while a request is pending, though not for every drug.

Common mistakes to avoid

  • Assuming the plan will treat the prescriber's judgment as enough. The plan wants documentation and evidence.
  • Letting the first denial end it. Many off-label requests are approved on appeal with better citations.
  • Waiting for the denial to gather evidence. Build the packet first.
  • Overlooking the Part D rule. In a Medicare drug plan, check whether the use is a medically accepted indication before investing in an appeal.
  • Missing the deadline. The notice gives the date. The claim denial appeal letter builder and the guide on deadlines can help you track it.
  • Paying cash without asking the plan. The cash price may be fine, but ask first whether a covered route exists.

Key takeaways

  • Off-label use is legal and common, but a plan does not have to cover it. Whether it pays depends on the plan's written policy, state law for insured plans, the evidence and the documentation.
  • Medicare Part D covers a drug only for a medically accepted indication: FDA-approved, or supported by named compendia. Commercial plans have more flexibility and look at evidence and medical necessity.
  • The prescriber builds the request: diagnosis, treatment history, rationale and citations. Ask for a copy, and for urgency to be marked when it applies.
  • If the plan denies, appeal. Add the evidence the first request lacked, ask for a peer-to-peer call and use external review, which often covers experimental or investigational denials. The notice states the deadlines.
  • Work out cash, alternative-drug and assistance options in parallel, and keep your treatment decisions with your prescriber.

Terms used in this guide

Related tools

Related guides

Latest on this topic